July 7, 2023
Molecular Mechanisms Leading to Diabetic Cardiomyopathy
Presented by G. Lopaschuk, PhD
American Diabetes Association Annual Meeting, 2023
Diagnosis of Diabetic Cardiomyopathy Based on Circulating Biomarkers Presented by J. Januzzi, MD, FACC, FESC
American Diabetes Association Annual Meeting, 2023
Cross-Sectional Analysis of a Large Cohort of Patients with DbCM Enrolled in a Longitudinal Study
Presented by J. Ezekowitz, MBBCh MSc
American Diabetes Association Annual Meeting, 2023
June 22, 2023
Diabetic Cardiomyopathy: Baseline Characteristics of Patients Enrolled in the ARISE-HF Trial
Presented by R. Perfetti, S. Del Prato, J. Rosenstock, J. Butler, J. Ezekowitz, N. Ibrahim, C. Lam, T. Marwick, WH. Wilson Tang, A. Urbinati, F. Zannad, J. Januzzi
European Society of Cardiology, 2023
Phenotypic Characterization of Echocardiographic Abnormalities in Patients with Diabetic Cardiomyopathy
Presented by T. Marwick, CSP. Lam, J. Butler, S. Del Prato, J. Ezekowitz, N E. Ibrahim, R. Perfetti, J. Rosenstock, WH. Wilson Tang, A. Urbinati, F. Zannad, J. Januzzi
European Society of Cardiology, 2023
NT-proBNP Levels in Diabetic Cardiomyopathy: Results from the ARISE-HF Trial
Presented by N. Ibrahim, J. Butler, WH. Wilson Tang, C. Lam, S. Del Prato, J. Ezekowitz, T. Marwick, R. Perfetti, J. Rosenstock, A. Urbinati, F. Zannad, J. Januzzi
European Society of Cardiology, 2023
November 2, 2022
Aldose Reductase Inhibition by AT-001 Alleviates Fibrosis and Adverse Remodelling in Diabetic Cardiomyopathy by Reducing Myocardial Fatty Acid Oxidation
Presented by Keshav Gopal, Qutuba G Karwi, S. Amirhossein Tabatabaei-Dakhili, Cory S Wagg, Liyan Zhang, Qiuyu Sun, Christina T Saed, Sai Panidarapu, Riccardo Perfetti, Ravichandran Ramasamy, John R Ussher, Gary D Lopaschuk
American Heart Association (AHA) Scientific Session 2022
Diabetic Cardiomyopathy Is Associated with Worsening Quality of Life Long Before the Development of Overt Heart Failure: Lessons from the Baseline Analysis of the ARISE-HF Trial
Presented by Alessia Urbinati, Riccardo Perfetti, Stella Wang, Sariah Persaud, Shoshana Shendelman, James L Januzzi Jr.
American Heart Association (AHA) Scientific Session 2022
November 2, 2022
Aldose Reductase Inhibition by AT-001 Alleviates Fibrosis and Adverse Remodelling in Diabetic Cardiomyopathy by Reducing Myocardial Fatty Acid Oxidation
Presented by Keshav Gopal, Qutuba G Karwi, S. Amirhossein Tabatabaei-Dakhili, Cory S Wagg, Liyan Zhang, Qiuyu Sun, Christina T Saed, Sai Panidarapu, Riccardo Perfetti, Ravichandran Ramasamy, John R Ussher, Gary D Lopaschuk
American Heart Association (AHA) Scientific Session 2022
Diabetic Cardiomyopathy Is Associated with Worsening Quality of Life Long Before the Development of Overt Heart Failure: Lessons from the Baseline Analysis of the ARISE-HF Trial
Presented by Alessia Urbinati, Riccardo Perfetti, Stella Wang, Sariah Persaud, Shoshana Shendelman, James L Januzzi Jr.
American Heart Association (AHA) Scientific Session 2022
May 9, 2022
Aldose Reductase Inhibitor AT-007 Prevents Mitochondrial Dysfunction and Neurodegeneration in Sorbitol Dehydrogenase Deficiency-Induced Neuropathy
Presented by Yi Zhu, MD, PhD, Assistant Scientist, University of Miami; Amanda Lobato, PhD Candidate, University of Miami; Adriana Rebelo, PhD, Scientist, University of Miami; Tijana Canic, Research Laboratory Technician, University of Miami; Sheyum Syed, PhD, MS, Associate Professor, University of Miami; Riccardo Perfetti, MD, PhD, Chief Medical Officer at Applied Therapeutics; Shoshana Shendelman, PhD, CEO and Founder at Applied Therapeutics; Stephan Züchner, MD, PhD, Professor and Chair, Department of Human Genetics, University of Miami; Grace Zhai, PhD, Professor of Molecular and Cellular Pharmacology
University of Miami 2022 Annual Meeting of the Peripheral Nerve Society
AT-007 Significantly Lowers Blood Sorbitol Levels in Patients with Hereditary Neuropathy Resulting from Sorbitol Dehydrogenase (SORD) Deficiency
Presented by Riccardo Perfetti, MD, PhD, Chief Medical Officer at Applied Therapeutics; Jahannaz Dastgir, DO, Director of Clinical Research at Applied Therapeutics; Shoshana Shendelman, PhD, CEO and Founder at Applied Therapeutics
2022 Annual Meeting of the Peripheral Nerve Society
Circulating Sorbitol Levels and Severity of Disease in Patients with Sorbitol Dehydrogenase (SORD) Deficiency
Presented by Riccardo Perfetti, MD, PhD, Chief Medical Officer at Applied Therapeutics; Shoshana Shendelman, PhD, CEO and Founder at Applied Therapeutics
2022 Annual Meeting of the Peripheral Nerve Society
Galactitol – But Not Gal-1p – Level is a Predictor of Disease Severity in Children with Classic Galactosemia on Galactose-Restricted Diet
Presented by Riccardo Perfetti, MD, PhD, Chief Medical Officer at Applied Therapeutics; Evan Bailey, MD, Executive Medical Director at Applied Therapeutics; Francesca Lawson, MD, FAHA, Vice President Clinical Regulatory Strategy at Applied Therapeutics; Stella Wang, MPH, Head Medical Projects & Data Analytics at Applied Therapeutics; Laura Saltonstall, MD, MBA, Vice President Medical Affairs, Head of Medical Strategy, Operations at Applied Therapeutics; Amanda Krumnow, PharmD, MBA, Vice President Medical Affairs at Applied Therapeutics; Shoshana Shendelman, PhD, CEO and Founder at Applied Therapeutics
43rd Annual Meeting of the Society for Inherited Metabolic Disorders
Baseline Disease Characteristics of 47 Pediatric Classic Galactosemia Patients in the ACTION-Galactosemia KIDS AT-007 Interventional Study Demonstrate the Multi-System Burden of Disease
Presented by Riccardo Perfetti, MD, PhD, Chief Medical Officer at Applied Therapeutics; Ayesha Ahmad, MBBS, Division of Pediatric Genetics, Metabolism and Genomic Medicine, University of Michigan; Han C. Phan, MD, Director of Clinical Research, Rare Disease Research LLC, Atlanta, GA; Janet Thomas, MD, Director, Inherited Metabolic Disease Clinic, University of Colorado School of Medicine and the Children’s Hospital Colorado; Francesca Lawson, MD, FAHA, Vice President Clinical Regulatory Strategy; Evan Bailey, MD, Executive Medical Director at Applied Therapeutics; Laura Saltonstall, MD, MBA, Vice President Medical Affairs, Head of Medical Strategy, Operations at Applied Therapeutics; Shoshana Shendelman, PhD, CEO and Founder at Applied Therapeutics
43rd Annual Meeting of the Society for Inherited Metabolic Disorders
November 23, 2021
Progressive Worsening of the Central Nervous System Phenotype in Children with Classic Galactosemia on Galactose Restricted Diet: A Cross-Sectional Analysis
Presented by Shoshana Shendelman, CEO and Founder of Applied Therapeutics; Riccardo Perfetti, Chief Medical Officer at Applied Therapeutics; Laura Saltonstall, VP, Medical Affairs at Applied Therapeutics
14th International Congress of Inborn Errors of Metabolism
Qualitative Interviews of Adults with Classic Galactosemia (CG) and their Caregivers: Disease Burden and Challenges with Daily Living
Presented by Shoshana Shendelman, CEO and Founder of Applied Therapeutics; Riccardo Perfetti, Chief Medical Officer at Applied Therapeutics; Laura Saltonstall, VP, Medical Affairs at Applied Therapeutics
14th International Congress of Inborn Errors of Metabolism
April 13, 2021
Progressive Worsening of Central Nervous System Phenotype in Children with Classic Galactosemia: a Cross-Sectional Analysis
Presented by Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied Therapeutics
2021 American College of Medical Genetics and Genomics Annual Clinical Genetics Meeting
March 23, 2021
October 26, 2020
Positive Biomarker Efficacy Results from the ACTION-Galactosemia Study
Presented by Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied Therapeutics
Post-Natal Galactitol Reduction is Associated with Normalization of CNS Phenotype in Animal Model of Galactosemia
Presented by Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied Therapeutics
American Society of Human Genetics (ASHG) 2020 Annual Meeting
September 23, 2020
AT-001: A Next Generation Aldose Reductase Inhibitor with Improved Potency, Selectivity and Specificity Protects from Cellular Damage Associated with Hyperglycaemia
Presented by Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied Therapeutics
Addressing Safety and Specificity with Aldose Reductase Inhibition: Development of AT-001 for Diabetic Cardiomyopathy
Presented by Riccardo Perfetti, MD, PhD, Chief Medical Officer of Applied Therapeutics
56th Annual Meeting of the European Association for the Study of Diabetes (EASD)
July 17-19, 2020
AT-007: Development of an Oral Treatment for Patients with Galactosemia
Presented by Shoshana Shendelman, PhD, CEO and Founder, Applied Therapeutics
Galactosemia Foundation Conference
ACTION-Galactosemia: Clinical Experience with Adult Galactosemia Patients and Path Forward
Presented by Riccardo Perfetti, MD, PhD, Chief Medical Officer, Applied Therapeutics
Galactosemia Foundation Conference
ACTION-Galactosemia Kids: Pediatric Study of AT-007 in Children with Galactosemia
Presented by Shoshana Shendelman, PhD, CEO and Founder, Applied Therapeutics
Galactosemia Foundation Conference
December 5-7, 2019
The ARISE-HF Study — Development of AT-001 for the Treatment of Diabetic Cardiomyopathy: Rationale and Study Design
Presented by Dr. James Januzzi, MD
December 4-7, 2019
Overcoming the Safety Challenges of Aldose Reductase Inhibition: Development of AT-001 for Diabetic Cardiomyopathy (presentation)
November 16-18, 2019
Clinical Assessment of AT-001, an Aldose Reductase Inhibitor in Development for Diabetic Cardiomyopathy: a 28 Day Proof of Concept Study (presentation – please download and view in Slideshow mode to hear presentation)
American Heart Association (AHA) Scientific Session 2019
Philadelphia, Pennsylvania
American Society of Human Genetics (ASHG) 2019 Annual Meeting
Houston, Texas
September 16-20, 2019
AT‑001 Significantly Reduces Cardiac Damage in an Animal Model of Diabetic Cardiomyopathy
55th Annual Meeting of the European Association for the Study of Diabetes (EASD)
Barcelona, Spain
September 13-16, 2019
Preclinical and Clinical Proof of Concept for Metabolic Intervention in Diabetic Cardiomyopathy
Heart Failure Society of America (HFSA) 23rd Annual Scientific Meeting
Philadelphia, PA
June 7-11, 2019
American Diabetes Association 79th Scientific Sessions
San Francisco, CA
May 25-28, 2019
European Society for Cardiology 6th World Congress on Acute Heart Failure
Athens, Greece
October 15-16, 2018
A Novel Investigational Treatment In Preclinical Development For Galactosemia
NORD Rare Summit 2018
Washington, D.C.
©2020 Applied Therapeutics All Rights Reserved